Resistant Mutants in H. influenzae."
-- Poster C2-200, titled "Antimicrobial Resistance Patterns among
Streptococcus pneumoniae Isolated from Children in the U.S. 2005-2006
Faropenem Surveillance Study."
-- Poster D-238, titled "An Evaluation of Dried MIC Susceptibility Plate
Compared to the CLSI (M7) Reference Broth Microdilution Method with
the New Antimicrobial Agent, Faropenem."
-- Poster C2-214, titled "Comparative Affinity of Faropenem to Penicillin
Binding Proteins (PBPs) of Pneumococci with Varying Beta-Lactam
Monday, September 17 at 1:00 PM, Hall D:
-- Poster L-480, titled "A Double-Blind, Randomized, Dose Ranging Study
to Evaluate the Safety of Faropenem Medoxomil (FM) at 300 or 600 mg
BID for Seven Days in Healthy Volunteers."
-- Poster L-481, titled "A Phase II Double-Blind, Randomized Trial
Comparing Faropenem Medoxomil at 300 mg BID for Seven Days and 600 mg
BID for Five Days in Subjects with Acute Maxillary Sinusitis Diagnosed
by Antral Tap."
Tuesday, September 18 at 11:15 AM, Hall D:
-- Poster G-980, titled "Monitoring Changes in Susceptibility of Middle
Ear Fluid (MEF), Nasopharyngeal (NP) and Oropharyngeal (OP) Pathogens
to Faropenem in a Phase II Acute Otitis Media (AOM) Study."
-- Poster G-983, titled "Use of Parent-reported Outcome Measure in Acute
Otitis Media Clinical Trials."
-- Poster G-987, titled "Dose-effect of Faropenem Medoxomil (FM) in the
Treatment of Acute Otitis Media."
Wednesday, September 19 at 11:15 AM, Hall D:
-- Poster A-1435, titled "Pharmacokinetic-Pharmacodynamic (PK-PD)
Assessment of Faropenem (FAR) in a Lethal Murine-Bacillus anthracis
(BA) Inhalation Post-Exposure Prophylaxis Model."
|SOURCE Replidyne, Inc.|
Copyright©2007 PR Newswire.
All rights reserved